Observational Studies

Cold Agglutinin Disease Real World EvidENCE (CADENCE) Registry until July 21, 2024 (3 year enrollment and 3 year follow up), from the following study sites, Austria, France, Germany, Italy, Japan, Netherlands, UK and the US. 

Registry Goals are to develop a large, international prospective registry of patients with CAD or CAS to better understand: 

1. Patient and clinical characteristics; patterns of use of CAD and CAS treatments; long-term clinical outcomes; patients’ health-related quality of life; and      healthcare resource utilisation 
2. Natural history of CAD and CAS including complications and comorbidities 
3. In addition, the study will include a drug registry component* to assess the safety and effectiveness of sutimlimab in patients with CAD in a real-world setting 

Please review the below Cadence Study Card PDF information and contact:

USRBDmedical@sanofi.com for more details.